JANUVIA (Sitagliptin) Compared With Sulfonylurea For Patients With Type 2 Diabetes

Pills

Merck (NYSE: MRK), known as MSD outside the United States and Canada, has announced results from a post-hoc pooled analysis showing patients with type 2 diabetes and mild renal impairment treated with JANUVIA®

Read more

Posted in Drugs